atrasentan has been researched along with carboplatin in 1 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C | 1 |
1 trial(s) available for atrasentan and carboplatin
| Article | Year |
|---|---|
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate | 2008 |